Generated by AI
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target fibroblast growth factor receptor (FGFR) biology. The company’s core work centers on designing small-molecule therapies for genetically defined cancers and rare skeletal disorders, using its SNÅP platform to support structure-guided drug discovery and rapid optimization. Tyra Biosciences is advancing oral dabogratinib across urologic cancers and skeletal dysplasia programs, alongside other FGFR-targeted candidates in its pipeline. Its current business is built around clinical development, translational research, and precision oncology, with an emphasis on conditions where specific genetic alterations drive disease. Headquartered in Carlsbad, California, Tyra Biosciences operates as a focused biotechnology developer serving the oncology and rare disease markets.
Website2656 State Street
Carlsbad, CA, 92008
United States
The latest articles about TYRA.
Tyra Biosciences reported a third quarter 2026 net loss of US$51.1 million and a basic loss per share of US$0.74 as spending on three clinical programs for dabogratinib continued. A recent financing round raised about US$400 million and extended funding visibility through 2030. The same update highlighted early Phase 2 SURF302 data for dabogratinib in FGFR3 altered bladder cancer, where a 79% overall response rate and an oral, potentially long term dosing profile could reshape how...
Summary of Sep 9's posts. Generated by AI.
No summary yet.
No summary yet.
Tyra Biosciences has delivered a 54.9% gain over the past 3 years, which means anyone looking at the stock today now has to ask whether that share price is still grounded in the company’s book value. For a business at Tyra Biosciences' stage, where hard assets and the balance sheet carry real weight, that question matters more than ever. The 54.9% return over 3 years puts real pressure on the idea that Tyra Biosciences' current valuation is still anchored to what its balance sheet actually...
No summary yet.
Summary of Sep 9's posts. Generated by AI.
Investors talking about TYRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.